查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1753910

反義及 RNAi 治療市場報告（依技術、給藥途徑、應用及地區）2025 年至 2033 年

Antisense & RNAi Therapeutics Market Report by Technology, Route of Administration, Application, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球反義及RNAi療法市場規模達18億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到33億美元，2025-2033年期間的複合年成長率（CAGR）為7.03%。全球遺傳疾病和慢性病的日益普及推動了該市場穩步成長，這需要創新療法、各主要市場支持性監管環境以加快新療法的核准和商業化，以及藥物輸送系統的持續技術進步。

反義和 RNAi 治療市場分析：

  • 主要市場促進因素：強大的技術促進因素推動市場的發展，例如藥物傳遞系統的快速進步，這增加了對細胞的治療影響和靶向特異性，以及遺傳疾病和慢性疾病的高發病率，這需要使用尖端的治療方式。
  • 主要市場趨勢：反義和 RNAi 治療行業的主要趨勢之一是其與基於獨特基因圖譜的個人化醫療緊密相關，旨在改善患者預後。
  • 地理趨勢：根據反義和 RNAi 治療市場分析，北美憑藉其優秀的醫療保健基礎設施、高額的醫療保健支出和友善的監管環境，在反義和 RNAi 治療市場佔據主導地位。
  • 競爭格局：這是一個充滿活力的市場，匯集了許多傳統醫藥市場參與者，例如頂尖製藥公司和成熟的創新企業。競爭格局將取決於對自有技術專利的爭奪、獲得監管機構的批准以及開展新的合作。
  • 挑戰與機會：反義及RNAi療法市場研究報告顯示，該產業面臨的主要挑戰在於開發和管理RNAi及反義療法的高成本與複雜性。反義療法也蘊含著機遇，因為它將使該行業成為創新和低成本藥物研發的場所，從而在尚未治癒的遺傳疾病領域取得突破。

反義和 RNAi 治療市場趨勢：

藥物輸送系統的技術進步

在這個市場中，主要促進因素之一是藥物輸送方法的持續發展。這些技術使RNA分子能夠乾淨且有效率地輸送至相關細胞，避免分解，進而提高治療效果。例如，脂質奈米顆粒和偶聯技術使反義寡核苷酸或siRNA的細胞攝取和平衡變得前所未有的微不足道。它提高了輸送效率，同時增強了療法與特定人體物質的相似度，而這些物質對於癌症、疾病和病毒感染等至關重要。反義和RNAi療法市場預測表明，這些療法將獲得大量的研究關注和資金投入。例如，諾華於2023年7月收購了DTx Pharma，這是一家專注於神經科學領域短干擾RNA療法的生物技術公司。同樣，這些收購也正在創造積極的市場前景。

遺傳性疾病和慢性病的盛行率不斷上升

群體中遺傳性疾病和慢性疾病的發生率不斷上升，有力地推動了反義和RNAi療法市場的成長。亨廷頓氏舞蹈症、某些類型的癌症以及各種遺傳性疾病只是少數常見且缺乏有效治療方法的疾病，這催生了對反義和RNAi療法的需求。此外，反義和RNAi療法作為候選致病基因的抑制劑，為疾病的治療提供了新的途徑。一方面，這些新藥最有可能應用在臨床上。另一方面，由於能夠針對特定基因，它們為目前無法透過傳統藥理學方法治療的患者提供了一種新的治療方式。這反過來又催生了對新生物製藥研發項目持續投資的明確需求。

支持新療法的監管環境

反義和RNAi療法的需求受到有利監管環境的推動。例如，美國食品藥物管理局（FDA）孤兒藥產品開發辦公室於2023年10月宣布，將在2024會計年度提供資金，用於承擔罕見疾病和病症自然史研究的費用。該RFA的既定目標是「提昇科學嚴謹性，促進合作，造福罕見疾病患者」。此外，FDA和EMA等全球衛生機構正在加快任何新療法的審查流程，包括RNAi和反義技術。同時，孤兒藥資格認定、加速核准和優先審查憑證等監管激勵措施也變得更加重要，因為它們將更有動力激勵製藥公司投入精力開發反義和RNAi療法。

反義和 RNAi 治療市場細分：

按技術分類：

  • RNA干擾
    • siRNA
    • miRNA
  • 反義RNA

反義 RNA 佔據反義和 RNAi 治療市場的大部分佔有率

反義RNA技術憑藉其成熟的方法和悠久的臨床應用歷史，在反義和RNAi治療市場中佔據領先地位。反義RNA的工作原理是合成RNA分子與特定的mRNA序列結合，進而阻斷致病標靶基因。此外，其廣泛的應用範圍從遺傳病理到各種慢性疾病（包括癌症），也奠定了其領先地位。此外，與其他RNAi技術不同，這些領先技術已在長達兩年的時間內廣泛應用，這使得人們能夠投入大量資源用於研究和開發其作用機制和給藥方式。此外，一些反義治療藥物已在RNAi技術市場上獲得FDA註冊，這最終證實了它們的有效性並鼓勵了進一步的投資。所有這些因素都有助於確保其在最大市場佔有率中的穩定發展；此外，在反義子領域，已經提交上市申請的有前景的藥物也已上市。因此，這項技術引領著RNA治療市場，並為該領域的突破奠定了基礎。

依給藥途徑分類：

  • 靜脈途徑
  • 皮下途徑
  • 鞘內途徑
  • 肺部輸送
  • 腹腔注射
  • 其他

肺部給藥佔業界最大佔有率

在反義和RNAi療法市場中，肺部給藥已成為給藥途徑的主導。其理由包括直接用於治療呼吸系統疾病，局部給藥可顯著提高療效。因此，能夠進入肺部並攜帶治療藥物，對於治療呼吸道合胞病毒和肺動脈高壓等疾病以及肺癌等疾病都具有顯著效果。它能夠使溶液在病灶處達到高濃度，減少全身性副作用，從而降低副作用，提高患者依從性並提高整體治療效果。此外，能夠有效地將藥物輸送至肺部組織的創新吸入器和解決方案也是一個重要方面。由於負荷不斷增加，人們面臨著盡可能提高治療有效性和針對性的壓力。因此，肺部給藥是RNAi技術市場的關鍵發展重點，並引領整體投資和創新配額。

按應用分類：

  • 腫瘤學
  • 心血管疾病（CVD）
  • 呼吸系統疾病
  • 腎臟疾病
  • 神經退化性疾病
  • 遺傳性疾病
  • 傳染病
  • 其他

按地區分類：

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

北美引領市場，佔據反義和 RNAi 治療市場最大佔有率

該報告還對所有主要區域市場進行了全面分析，包括北美（美國和加拿大）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告指出，北美是反義和RNAi療法最大的區域市場。

北美是反義和RNAi療法市場最大的區域。這項優勢主要歸功於該地區成熟的生物技術和製藥研究基礎設施。此外，各國政府和其他全球衛生組織提供的空前支持，為反義和RNAi治療平台發展所需的研究和先進開發創造了有利環境。根據反義和RNAi療法市場分析，該地區多家領先的生物技術和製藥公司的存在，創造了激烈的競爭並促進了創新，加速了開發機會和產品上市。此外，北美積極的監管環境，例如美國食品藥物管理局（FDA）的積極參與，已快速核准多種用於治療多種遺傳和慢性疾病的RNA藥物，也為RNA療法市場提供了支持。此外，該地區癌症和遺傳性疾病等目標疾病的高發生率也創造了反義和RNAi療法的需求。因此，北美引領反義和 RNAi 治療市場，是技術開發的主導者，也是基於 RNA 的治療產品的主要市場。

競爭格局：

市場研究報告還對市場競爭格局進行了全面分析，並提供了所有主要公司的詳細資料。反義和 RNAi 治療行業的主要市場參與者包括：

  • Alnylam製藥公司
  • Arbutus 生物製藥公司
  • Arrowhead Pharmaceuticals Inc.
  • Benitec Biopharma 有限公司
  • Bio-Path 控股公司
  • Dicerna Pharmaceuticals Inc.（諾和諾德公司）
  • 伊奧尼斯製藥公司
  • OliX製藥公司
  • Phio製藥公司
  • Sarepta治療公司
  • 沉默治療公司
  • 聖諾製藥公司

市場主要參與者正日益參與研發，以豐富其基因治療產品組合。他們積極建立策略合作夥伴關係，收購小型生物技術公司，或與學術機構和研發中心合作，以利用新興顛覆性技術並加速藥物開發。同時，考慮到高昂的成本和開發風險，公司在臨床試驗方面投入了大量資金，以確保其在更廣泛的應用組合（尤其是在基因轉移性疾病領域）中的有效性和安全性。與監管機構的合作可以提升公司的競爭力，並引導他們更快推出新藥。這項措施對於創造競爭優勢以及積極的反義和RNAi療法市場前景至關重要。

本報告回答的關鍵問題

  • 全球反義和 RNAi 治療市場有多大
  • 2025 年至 2033 年期間全球反義和 RNAi 治療市場的預期成長率是多少
  • 推動全球反義和 RNAi 治療市場的關鍵因素有哪些
  • COVID-19 對全球反義和 RNAi 治療市場有何影響
  • 根據技術，全球反義和 RNAi 治療市場如何分類
  • 根據給藥途徑，全球反義和 RNAi 治療市場如何分類
  • 全球反義和 RNAi 治療市場的主要區域有哪些
  • 全球反義和 RNAi 治療市場的主要參與者/公司有哪些

本報告回答的關鍵問題

  • 全球反義和RNAi治療市場有多大？ 2025-2033年期間，全球反義和RNAi治療市場的預期成長率是多少？
  • 推動全球反義和 RNAi 治療市場發展的關鍵因素有哪些？
  • COVID-19 對全球反義和 RNAi 治療市場有何影響？
  • 根據技術，全球反義和 RNAi 治療市場如何分佈？
  • 根據給藥途徑，全球反義和 RNAi 治療市場如何分佈？
  • 全球反義和 RNAi 治療市場的關鍵區域有哪些？
  • 全球反義和 RNAi 治療市場的主要參與者/公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球反義與 RNAi 治療市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依技術

  • RNA干擾
    • 關鍵部分
      • siRNA
      • miRNA
  • 反義RNA

第7章：市場區隔：依行政途徑

  • 靜脈途徑
  • 皮下途徑
  • 鞘內途徑
  • 肺部輸送
  • 腹腔注射
  • 其他

第 8 章：市場區隔：按應用

  • 腫瘤學
  • 心血管疾病（CVD）
  • 呼吸系統疾病
  • 腎臟疾病
  • 神經退化性疾病
  • 遺傳性疾病
  • 傳染病
  • 其他

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第10章：SWOT分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第13章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Alnylam Pharmaceuticals Inc.
    • Arbutus Biopharma Corporation
    • Arrowhead Pharmaceuticals Inc.
    • Benitec Biopharma Ltd.
    • Bio-Path Holdings Inc.
    • Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
    • Ionis Pharmaceuticals Inc.
    • OliX Pharmaceuticals Inc.
    • Phio Pharmaceuticals Corp.
    • Sarepta Therapeutics Inc.
    • Silence Therapeutics
    • Sirnaomics Inc.
Product Code: SR112025A6549

The global antisense & RNAi therapeutics market size reached USD 1.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.3 Billion by 2033, exhibiting a growth rate (CAGR) of 7.03% during 2025-2033. The market is experiencing steady growth driven by the increasing prevalence of genetic and chronic diseases globally necessitates innovative treatments, supportive regulatory environments across major markets to expedite the approval and commercialization of new therapies, and continuous technological advancements in drug delivery systems.

Antisense & RNAi Therapeutics Market Analysis:

  • Major Market Drivers: The market is driven by powerful technological drivers such as rapid advancements in drug delivery systems, which increased therapeutic impact on cells and targeting specificity, and a high incidence of genetic disorders and chronic diseases, which requires the use of cutting-edge therapeutic modalities.
  • Key Market Trends: One of the major antisense & RNAi therapeutics industry trends is its tight association with the personalization of medicine based on unique genetic profiles and aimed at improving patient outcomes.
  • Geographical Trends: According to the antisense & RNAi therapeutics market analysis, North America dominates the market for Antisense & RNAi Therapeutics due to its excellent healthcare infrastructure, high healthcare spending, and friendly regulatory environment.
  • Competitive Landscape: This is a dynamic market with a pool of traditional drug market players such as top pharmaceutical companies and innovators that have established themselves. The competitive space will have to determine the battle for patents of owned technologies, achieving the green light from the regulatory authorities, and making new collaborations.
  • Challenges and Opportunities: The antisense & RNAi therapeutics market research report shows that the industry's major challenge is the high cost and complexity of developing and managing RNAi and antisense-based therapies. The latter is also an opportunity since it will transform the sector into loci of innovation and low-cost drug discovery resulting in breakthroughs in untreated genetic diseases.

Antisense & RNAi Therapeutics Market Trends:

Technological advancements in drug delivery systems

In this market, one of the major drivers is the continuing developments of drug delivery methods. These technologies allow RNA molecules to be delivered to relevant cells cleanly and efficiently, in a pattern that avoids degradation and hence provided enhanced efficacy in terms of therapy. For example, lipid nanoparticles and conjugate technologies enabled the previously negligible cellular uptake and balance of antisense oligonucleotides or siRNA. It increases delivery while enhancing the degree of similarity in which therapeutics are suitable to target specific human material, which is critical in cancer, disorders, and viral infections, among other things. The antisense & RNAi therapeutics market forecast indicates that these treatments will gain substantial research attention and financial investment. For instance, Novartis acquired DTx Pharma in July 2023, which is a biotechnology company concentrating on short-interfering RNA therapy for neuroscience indications. Similarly, these acquisitions are creating a positive market outlook.

Increasing prevalence of genetic disorders and chronic diseases

The accelerating incidences of genetic and chronic diseases among the masses is significantly supporting the antisense & RNAi therapeutics market growth. Huntington's, certain types of cancer, and a wide range of hereditary genetic conditions are just a few examples of prevalent illnesses with few efficient treatments, which create demand for antisense & RNAi therapeutics. Along with this, Antisense and RNAi treatment options provide a new avenue as candidate disease-predisposing genes' repressors. On one hand, the new drugs have the best prospects of being included in clinical practice. On the other - by having the ability to target specific genes, they represent a new treatment modality for patients with conditions that are currently unmanageable using conventional pharmacological methods. This, in turn, generates a clear need for continued investment in new biopharmaceutical R&D projects.

Supportive regulatory environment for novel therapies

The antisense & RNAi therapeutics demand is impelled by the supportive regulatory environment. For instance, in October 2023, The Food and Drug Administration's Office of Orphan Products Development announced the availability of funds for fiscal year (FY) 2024 to help underwrite the costs of conducting natural history studies on rare diseases and conditions. The stated goal of this RFA is "to advance scientific rigor and collaboration for the benefit of patients with rare diseases or conditions." In addition, global health authorities, such as the FDA and EMA, are introducing faster review processes for any new therapies, inclusive of RNAi and antisense technology. Meanwhile, regulatory incentives like orphan drug status, accelerated approval, and priority review vouchers gain even more relevance since they give pharmaceutical companies even more incentive to put effort into the development of antisense and RNAi therapies.

Antisense & RNAi Therapeutics Market Segmentation:

Breakup by Technology:

  • RNA Interference
    • siRNA
    • miRNA
  • Antisense RNA

Antisense RNA accounts for the majority of the antisense & RNAi therapeutics market share

Antisense RNA technology is the leader in the Antisense & RNAi Therapeutics market due to its mature methodology and the longest history of clinical application. Antisense RNA acts based on synthetic RNA molecules adhering to specific mRNA sequences, and it results in the blockade of target genes responsible for disease. In addition, the broadest possible range of applications from genetic pathologies to chronic diseases of various origins, including cancer, primarily has ensured its leader position. Apart from this, unlike other RNAi technologies, the leaders have already spent up to two years of widespread use, which allowed the investment of large resources in research and developing mechanisms of action and delivery. Moreover, some antisense therapeutic agents are already on the RNAi technology market with active FDA registration, which ultimately confirms their effectiveness and encourages further investment. All these factors contribute to ensuring a steady drill with the most significant share; even more, promising drugs already filed to proliferation can be observed in the antisense subfield. Thus, this technology leads the RNA based therapeutics market and lays the foundation for breakthroughs in this field.

Breakup by Route of Administration:

  • Intravenous Route
  • Subcutaneous Route
  • Intrathecal Route
  • Pulmonary Delivery
  • Intraperitoneal Injection
  • Others

Pulmonary delivery holds the largest share of the industry

In the Antisense & RNAi therapeutics market, pulmonary delivery has taken the lead in terms of administration channels. There are several justifications, including direct utilization in curing respiratory conditions, in which localized delivery significantly increases the effectiveness. Thus, the ability to access the lungs and carry therapeutic agents is effective in treating diseases such as respiratory syncytial virus and pulmonary arterial hypertension as well as directing to lung cancer. It enabled high concentration of the solution on the site of the disease, limited systemic, hence lower side effects, improved patient adherence, and the overall effectiveness of treatment. Moreover, innovative inhalers and solutions that allow efficient drug delivery to lung tissues are also an important aspect. Due to the increasing load, there is pressure to make therapy as effective and targeted as possible. Therefore, pulmonary delivery serves as a key development focus of the RNAi technology market and directs the overall investment and innovation quotas.

Breakup by Application:

  • Oncology
  • Cardiovascular Diseases (CVDs)
  • Respiratory Disorders
  • Renal Diseases
  • Neurodegenerative Disorders
  • Genetic Disorders
  • Infectious Diseases
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest antisense & RNAi therapeutics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for antisense & RNAi therapeutics.

North America is the largest regional segment in the Antisense & RNAi therapeutics market. This prominence is primarily due to the region's mature biotechnological and pharmaceutical research infrastructure. Additionally, unprecedented support from various national governments and other global health organizations has created a conducive environment for research and the advanced development required to progress antisense and RNAi therapy platforms. According to the antisense & RNAi therapeutics market analysis, the presence of several leading biotech and pharmaceutical companies in the region, which has created fierce competition and promoting innovation, has accelerated development opportunities as well as product launch. Additionally, North America's proactive regulatory environment, the exceptional participation of the FDA, which has fast-tracked many RNA-based drugs for several genetic and chronic disease conditions, supports the RNA based therapeutics market. Moreover, the high prevalence of target diseases, including cancer and genetic disorders, in the region creates antisense & RNAi therapeutics demand. Thus, North America leads the Antisense & RNAi Therapeutics market, as a dominant player in technology development and also as the primary market for RNA-based therapeutic products.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the antisense & RNAi therapeutics industry include:

  • Alnylam Pharmaceuticals Inc.
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals Inc.
  • Benitec Biopharma Ltd.
  • Bio-Path Holdings Inc.
  • Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
  • Ionis Pharmaceuticals Inc.
  • OliX Pharmaceuticals Inc.
  • Phio Pharmaceuticals Corp.
  • Sarepta Therapeutics Inc.
  • Silence Therapeutics
  • Sirnaomics Inc.

The major players in the market are increasingly involved in research and development to diversify their genetic therapy portfolios. They are actively engaging in strategic partnerships, taking over small biotech companies, or collaborating with academic institutions and R&D centers to capitalize on emerging and disruptive technologies and fast-track drug development. In confluence with this, considering the high costs and development risks, companies make significant investments in clinical trials to guarantee their effectiveness and safety in a wider applications portfolio, especially in AlNM diseases. Collaboration with the regulatory bodies enhances the companies' competitive performance and guides them along the way to bring new drugs faster. This initiative is vital for creating competitive advantages and a positive antisense & RNAi therapeutics market outlook.

Key Questions Answered in This Report

  • 1.How big is the global antisense & RNAi therapeutics market?
  • 2.What is the expected growth rate of the global antisense & RNAi therapeutics market during 2025-2033?
  • 3.What are the key factors driving the global antisense & RNAi therapeutics market?
  • 4.What has been the impact of COVID-19 on the global antisense & RNAi therapeutics market?
  • 5.What is the breakup of the global antisense & RNAi therapeutics market based on the technology?
  • 6.What is the breakup of the global antisense & RNAi therapeutics market based on the route of administration?
  • 7.What are the key regions in the global antisense & RNAi therapeutics market?
  • 8.Who are the key players/companies in the global antisense & RNAi therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antisense & RNAi Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 RNA Interference
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 siRNA
      • 6.1.2.2 miRNA
    • 6.1.3 Market Forecast
  • 6.2 Antisense RNA
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Intravenous Route
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Subcutaneous Route
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Intrathecal Route
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pulmonary Delivery
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Intraperitoneal Injection
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Cardiovascular Diseases (CVDs)
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Respiratory Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Renal Diseases
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Neurodegenerative Disorders
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Genetic Disorders
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Infectious Diseases
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast
  • 8.8 Others
    • 8.8.1 Market Trends
    • 8.8.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Alnylam Pharmaceuticals Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Arbutus Biopharma Corporation
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Arrowhead Pharmaceuticals Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 Benitec Biopharma Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Bio-Path Holdings Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Ionis Pharmaceuticals Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 OliX Pharmaceuticals Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Phio Pharmaceuticals Corp.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Sarepta Therapeutics Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Silence Therapeutics
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
    • 14.3.12 Sirnaomics Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio

List of Figures

  • Figure 1: Global: Antisense & RNAi Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Antisense & RNAi Therapeutics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Antisense & RNAi Therapeutics Market: Breakup by Technology (in %), 2024
  • Figure 5: Global: Antisense & RNAi Therapeutics Market: Breakup by Route of Administration (in %), 2024
  • Figure 6: Global: Antisense & RNAi Therapeutics Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Antisense & RNAi Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Antisense & RNAi Therapeutics (RNA Interference) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Antisense & RNAi Therapeutics (RNA Interference) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Antisense & RNAi Therapeutics (Oncology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Antisense & RNAi Therapeutics (Oncology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: Antisense & RNAi Therapeutics (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: Antisense & RNAi Therapeutics (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: North America: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: North America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: United States: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: United States: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Canada: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Canada: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Asia-Pacific: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Asia-Pacific: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: China: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: China: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Japan: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Japan: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: India: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: India: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: South Korea: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: South Korea: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Australia: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Australia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Indonesia: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Indonesia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Europe: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Europe: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Germany: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Germany: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: France: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: France: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: United Kingdom: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: United Kingdom: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Italy: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Italy: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Spain: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Spain: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Russia: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Russia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Latin America: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Latin America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Brazil: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Brazil: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Mexico: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Mexico: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: Middle East and Africa: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 87: Middle East and Africa: Antisense & RNAi Therapeutics Market: Breakup by Country (in %), 2024
  • Figure 88: Middle East and Africa: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Global: Antisense & RNAi Therapeutics Industry: SWOT Analysis
  • Figure 90: Global: Antisense & RNAi Therapeutics Industry: Value Chain Analysis
  • Figure 91: Global: Antisense & RNAi Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antisense & RNAi Therapeutics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 3: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 4: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Antisense & RNAi Therapeutics Market: Competitive Structure
  • Table 7: Global: Antisense & RNAi Therapeutics Market: Key Players